CN1418679A - Medicine compositions for treating hepatitis, and its prepn. method - Google Patents
Medicine compositions for treating hepatitis, and its prepn. method Download PDFInfo
- Publication number
- CN1418679A CN1418679A CN 02153441 CN02153441A CN1418679A CN 1418679 A CN1418679 A CN 1418679A CN 02153441 CN02153441 CN 02153441 CN 02153441 A CN02153441 A CN 02153441A CN 1418679 A CN1418679 A CN 1418679A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- hepatitis
- concentrated
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 19
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims 8
- 229940079593 drug Drugs 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 241000756943 Codonopsis Species 0.000 claims abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000002131 composite material Substances 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a Chinese medicine composite for curing hepatitis and its preparation method. Said composite is composed of 13 Chinese medicinal materials of codonopsis root, prepared bupleurum root, white peony root, Chinese angelica root, poria and others.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of hepatitis and preparation method thereof.
Chronic hepatitis, liver cirrhosis are long with the course of disease, the symptom delay, and the impaired in various degree grade of liver function is a main feature.Conditions of patients is not healed repeatedly, and feelings will is lost smooth, the liver failing to maintain the normal flow of QI, and depression and stagnation of QI is then seen dull pain in liver; Prolonged illness must be empty, is added with that liver disease affecting spleen, and liver insulting spleen, weakness of the spleen and stomach, and dysfunction of the spleen in transportation, stomach loses and is received, and poor appetite is then seen by taste lifting mistake department, and big loose stool approaches; Spleen governing limbs muscle, weakness of the spleen and stomach, limbs fatigue then, fatiguability; Acute hepatitis is damp and hot for suffering from, the course of disease with the passing of time, damp and hot stopping over, weakness of the spleen and stomach loses in fortuneization increasingly, endogenous dampness accumulates heat-transformation of a specified duration, causes damp and hot accumulateing in middle Jiao eventually, so see bitter taste in the mouth and dry throat; Pathogen usually intruding into collateral in protracted disease, irritability stasis, hematogenous blockage, blood-stasis internal-depression, the then visible side of body is mass in the abdomen down, by do not move; Light purplish tongue has the tooth seal, yellow, thin and slightly greasy fur, and thready and stringy pulse is stagnation of liver-QI with deficiency of the spleen, presss from both sides resembling of damp and hot blood stasis.Primary disease pathology character is deficiency in origin and excess in superficiality, and the pathogenesis key is stagnation of liver-QI with deficiency of the spleen, the damp and hot blood stasis of folder of holding concurrently, control when soothing liver and strengthening spleen for earlier, assistant is with Qinghua dissipating blood stasis.
The object of the invention be to provide a kind of clinical efficacy significantly, the Chinese medicine of the treatment hepatitis that has no side effect of taking convenience and preparation method thereof.
Technical solution of the present invention is achieved in that
The raw material of weight portion as described below
150～450 parts of 60～180 portions of Radix Paeoniae Albas of Radix Codonopsis 150～450 parts of systems Radix Bupleuri
60～180 parts of 150～450 parts of Rhizoma Atractylodis Macrocephalae (parched)s of 90～270 parts of Poria of Radix Angelicae Sinensis
120～360 parts of 150～450 parts of Rhizoma Polygoni Cuspidati of 90～270 parts of Herba Taraxacis of Fructus Aurantii (parched)
30～90 parts in 90～270 parts of Semen Persicaes of 150～450 parts of Radix Salviae Miltiorrhizaes of Spica Prunellae
15～45 parts of Carapax Trionycis
Get the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, system Radix Bupleuri, Radix Angelicae Sinensis, Fructus Aurantii, Rhizoma Polygoni Cuspidati, with 40%～80 alcohol reflux 2～3 times, each 1～3 hour, filter merging filtrate, decompression recycling ethanol, be concentrated into relative density and be 1.05～1.25 clear paste, measure temperature and be 50 ℃, standby; Medicinal residues after the alcohol extraction and Radix Codonopsis, the Radix Paeoniae Alba, Poria, Herba Taraxaci, Spica Prunellae, Semen Persicae, Carapax Trionycis decoct with water secondary, and each 1～3 hour, collecting decoction, filter, it is 1.05～1.20 that filtrate is concentrated into relative density, and measuring temperature is 60 ℃, be blended into above-mentioned clear paste, filtrate is concentrated into relative density and is about 1.25～1.35 thick paste, and measuring temperature is 60 ℃, drying is pulverized, and adds starch 50～150g and sucrose 150～450g, mixing, system granule, particle drying, make 1000g altogether, packing, promptly.
The present invention treats the pharmaceutical composition of hepatitis through laboratory observation, inhibition effect to infected duck serum DHBV-DNA level is remarkable, non-toxic reaction all has significant difference to the average suppression ratio of HbeAg in the 8th day supernatant of 2.25.15 cell culture, and tangible dose-effect relationship is arranged; Can make acute liver damage animal pattern Serum ALT, AST activity little than the matched group ascensional range, as seen the liver histological pathological observation obviously alleviates the rats'liver damage.The activity of ALT, AKP in the Rats with Acute Liver Injury serum is descended, ALB, BPC are raise, improve hepatic tissue pathology and change, reduce hydroxyprolin levels in the hepatic tissue; The immunologic liver injury mice there is function for protecting liver and reducing enzyme activity, can reduces ALT, AST unit of activity, reduce hepatosplenomegaly and organ coefficient thereof, alleviate the pathological lesion of hepatic tissue; Immune hyperfunction state to the immunologic liver injury mice has obvious inhibitory action, and the phagocytic percentage of peritoneal macrophage and phagocytic index are descended, and serum hemolysin HC50 reduces, and the inductive splenic t-cell propagation of ConA is reduced; The immunologic hypofunction mice there is facilitation, can improve mononuclear phagocyte carbon clearance index, improve the phagocytic percentage and the phagocytic index of peritoneal macrophage, improve serum hemolysin HC50, improve the inductive splenic t-cell propagation of ConA, improve the lymphoblastic percentage rate that PHA stimulates peripheral blood lymphocyte to transform, significance is all arranged.Above-mentioned experimental result shows that medicine of the present invention has soothing liver and strengthening spleen, heat-clearing and toxic substances removing, and the effect of softening the hard mass dissipating blood stasis is used for chronic active hepatitis, chronic persistent hepatitis, liver cirrhosis, hepatitis B virus carriers.
Clinical test results shows that the pharmaceutical composition that the present invention treats hepatitis has soothing liver and strengthening spleen, and heat-clearing and toxic substances removing, softening the hard mass loose and become silted up hepatoprotective, effects such as anti-hepatic fibrosis can be used for stagnation of liver-QI with deficiency of the spleen, the noxious dampness internal resistance, acute and chronic hepatitis, liver cirrhosis, treatment of conditions such as liver function injury.Experimental example 1: the tetrachloro charcoal is caused the influence of rabbit experiment liver damage:
Rabbit is divided into 6 groups at random: normal control group, ccl4 (0.1ml/kg) model group, ccl4+ bifendate (60mg/kg) group, 3 dosage groups of ccl4+ pharmaceutical composition of the present invention.Behind the lumbar injection ccl4, the continuous gastric infusion of each treated animal 5 days was put to death animal in 1 hour after the last administration, got blood and dissection immediately, got liver and carried out histochemistry and pathological examination.The result shows: the heavy dose of group of pharmaceutical composition of the present invention has the SGPT of reduction value trend; LDH content is significantly increased than the damage group in the pathologic finding high dose group hepatic tissue, and lobules of liver central zone LDH content increases to some extent, and hepatic glycogen is evenly distributed, and lobules of liver central zone and paripheral zone glycogen increase to some extent than damage group; High dose group is loose to the hepatocyte endochylema, lipoid degeneration, acidophilia and necrosis all have obvious protective effect.The protective effect of pharmaceutical composition of the present invention is similar to the bifendate group, and latter's effect of reducing enzyme levels is stronger, sees the following form.
Grouping number of animals SGPT X ± SD P value
Normal control group 10 35.43 ± 7.93
Model control group 10 502.08 ± 32.22
Bifendate group 9 211.41 ± 50.42＜0.01
Pharmaceutical composition high dose group 10 237.38 ± 38.90＜0.01 of the present invention
Dosage group 9 339.68 ± 46.22＜0.05 in the pharmaceutical composition of the present invention
Pharmaceutical composition low dose group 10 489.91 ± 64.00 of the present invention
Embodiment 1:
Radix Codonopsis 300g system Radix Bupleuri 120g Radix Paeoniae Alba 300g
Radix Angelicae Sinensis 180g Poria 300g Rhizoma Atractylodis Macrocephalae (parched) 120g
Fructus Aurantii (parched) 180g Herba Taraxaci 300g Rhizoma Polygoni Cuspidati 240g
Spica Prunellae 300g Radix Salviae Miltiorrhizae 180g Semen Persicae 60g
Carapax Trionycis 30g
Get the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, system Radix Bupleuri, Radix Angelicae Sinensis, Fructus Aurantii, Rhizoma Polygoni Cuspidati, with 60% alcohol reflux secondary, each 1.5 hours, filter, merging filtrate, decompression recycling ethanol is concentrated into relative density and is 1.05～1.25 clear paste, measures temperature and is 60 ℃, and is standby; Medicinal residues after the alcohol extraction and Radix Codonopsis, the Radix Paeoniae Alba, Poria, Herba Taraxaci, Spica Prunellae, Semen Persicae, Carapax Trionycis decoct with water secondary, each 1.5 hours, collecting decoction, filter, it is 1.10～1.15 that filtrate is concentrated into relative density, and measuring temperature is 60 ℃, be blended into above-mentioned clear paste, filtrate is concentrated into relative density and is about 1.30～1.35 thick paste, and measuring temperature is 60 ℃, drying, pulverize, add starch 100g and sucrose 300g, mixing is made wetting agent system granule with 85% ethanol, particle drying, make 1000g altogether, packing, promptly.
Embodiment 2:
Radix Codonopsis 250g system Radix Bupleuri 100g Radix Paeoniae Alba 250g
Radix Angelicae Sinensis 200g Poria 250g Rhizoma Atractylodis Macrocephalae (parched) 100g
Fructus Aurantii (parched) 200g Herba Taraxaci 250g Rhizoma Polygoni Cuspidati 200g
Spica Prunellae 250g Radix Salviae Miltiorrhizae 200g Semen Persicae 80g
Carapax Trionycis 25g
Get the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, system Radix Bupleuri, Radix Angelicae Sinensis, Fructus Aurantii, Rhizoma Polygoni Cuspidati, with 60% alcohol reflux secondary, each 1.5 hours, filter, merging filtrate, decompression recycling ethanol is concentrated into relative density and is 1.05～1.25 clear paste, measures temperature and is 60 ℃, and is standby; Medicinal residues after the alcohol extraction and Radix Codonopsis, the Radix Paeoniae Alba, Poria, Herba Taraxaci, Spica Prunellae, Semen Persicae, Carapax Trionycis decoct with water secondary, each 1.5 hours, collecting decoction, filter, it is 1.10～1.15 that filtrate is concentrated into relative density, and measuring temperature is 60 ℃, be blended into above-mentioned clear paste, filtrate is concentrated into relative density and is about 1.30～1.35 thick paste, and measuring temperature is 60 ℃, drying, pulverize, add starch 100g and sucrose 300g, mixing is made wetting agent system granule with 85% ethanol, particle drying, make 1000g altogether, packing, promptly.
Claims (7)
1, a kind of pharmaceutical composition for the treatment of hepatitis is characterized in that this medicine made by following bulk drugs:
150～450 parts of 60～180 portions of Radix Paeoniae Albas of Radix Codonopsis 150～450 parts of systems Radix Bupleuri
60～180 parts of 150～450 parts of Rhizoma Atractylodis Macrocephalae (parched)s of 90～270 parts of Poria of Radix Angelicae Sinensis
120～360 parts of 150～450 parts of Rhizoma Polygoni Cuspidati of 90～270 parts of Herba Taraxacis of Fructus Aurantii (parched)
30～90 parts in 90～270 parts of Semen Persicaes of 150～450 parts of Radix Salviae Miltiorrhizaes of Spica Prunellae
15～45 parts of Carapax Trionycis
2, a kind of pharmaceutical composition for the treatment of hepatitis as claimed in claim 1 is characterized in that being made by following bulk drugs:
300 parts of 120 portions of Radix Paeoniae Albas of Radix Codonopsis 300 parts of systems Radix Bupleuri
120 parts of 300 parts of Rhizoma Atractylodis Macrocephalae (parched)s of 180 parts of Poria of Radix Angelicae Sinensis
240 parts of 300 parts of Rhizoma Polygoni Cuspidati of 180 parts of Herba Taraxacis of Fructus Aurantii (parched)
60 parts in 180 parts of Semen Persicaes of 300 parts of Radix Salviae Miltiorrhizaes of Spica Prunellae
30 parts of Carapax Trionycis
3, as claim 1,2 described a kind of preparation of drug combination methods for the treatment of hepatitis, it is characterized in that this prescription method is: get the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, system Radix Bupleuri, Radix Angelicae Sinensis, Fructus Aurantii, Rhizoma Polygoni Cuspidati, with 40%～80 alcohol reflux 2～3 times, each 1～3 hour, filter merging filtrate, decompression recycling ethanol, be concentrated into relative density and be 1.05～1.25 clear paste, measure temperature and be 50 ℃, standby; Medicinal residues after the alcohol extraction and Radix Codonopsis, the Radix Paeoniae Alba, Poria, Herba Taraxaci, Spica Prunellae, Semen Persicae, Carapax Trionycis decoct with water secondary, and each 1～3 hour, collecting decoction, filter, it is 1.05～1.20 that filtrate is concentrated into relative density, and measuring temperature is 60 ℃, be blended into above-mentioned clear paste, filtrate is concentrated into relative density and is about 1.25～1.35 thick paste, and measuring temperature is 60 ℃, drying is pulverized, and adds adjuvant, mixing, system granule, particle drying, packing is made 1000g, promptly altogether.
4, a kind of preparation of drug combination method for the treatment of hepatitis as claimed in claim 3, it is characterized in that this method is: get the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, system Radix Bupleuri, Radix Angelicae Sinensis, Fructus Aurantii, Rhizoma Polygoni Cuspidati, with 60% alcohol reflux secondary, each 1.5 hours, filter merging filtrate, subtract decompression recycling ethanol, be concentrated into relative density and be 1.10～1.25 clear paste, measure temperature and be 50 ℃, standby; Medicinal residues after the alcohol extraction and Radix Codonopsis, the Radix Paeoniae Alba, Poria, Herba Taraxaci, Spica Prunellae, Semen Persicae, Carapax Trionycis decoct with water secondary, and each 1.5 hours, collecting decoction, filter, it is 1.10～1.15 that filtrate is concentrated into relative density, and measuring temperature is 60 ℃, be blended into above-mentioned clear paste, filtrate is concentrated into relative density and is about 1.30～1.35 thick paste, and measuring temperature is 60 ℃, drying is pulverized, and adds adjuvant, mixing, system granule, particle drying, make 1000g altogether, packing, promptly.
5, as claim 3,4 described a kind of preparation of drug combination methods for the treatment of hepatitis, make wetting agent with 85% ethanol when it is characterized in that making granule.
6, as claim 3,4 described a kind of preparation of drug combination methods for the treatment of hepatitis, it is characterized in that adjuvant is starch 50～150g and sucrose 150～450g.
7, a kind of preparation of drug combination method for the treatment of hepatitis as claimed in claim 6 is characterized in that adjuvant is starch 100g and sucrose 300g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153441 CN1234381C (en) | 2002-11-27 | 2002-11-27 | Medicine compositions for treating hepatitis, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153441 CN1234381C (en) | 2002-11-27 | 2002-11-27 | Medicine compositions for treating hepatitis, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1418679A true CN1418679A (en) | 2003-05-21 |
| CN1234381C CN1234381C (en) | 2006-01-04 |
Family
ID=4752252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02153441 Expired - Lifetime CN1234381C (en) | 2002-11-27 | 2002-11-27 | Medicine compositions for treating hepatitis, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234381C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743479A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparing method thereof |
| CN102743477A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
| CN102743480A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
| CN102743478A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparing method thereof |
| CN103735949A (en) * | 2013-12-30 | 2014-04-23 | 卢保健 | Traditional Chinese medicine for treating liver cancer and hepatic injury due to hepatitis B |
| CN105169274A (en) * | 2015-10-10 | 2015-12-23 | 崇州市地龙海龙生物制品开发研究所 | Preparation method of quick-acting liver pill |
| CN106620057A (en) * | 2016-12-12 | 2017-05-10 | 广西防城港常春生物技术开发有限公司 | Anti-hepatic fibrosis Zhuang medicine preparation and preparation method thereof |
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
-
2002
- 2002-11-27 CN CN 02153441 patent/CN1234381C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743479A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparing method thereof |
| CN102743477A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
| CN102743480A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof |
| CN102743478A (en) * | 2012-07-27 | 2012-10-24 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating hepatitis and preparing method thereof |
| CN103735949A (en) * | 2013-12-30 | 2014-04-23 | 卢保健 | Traditional Chinese medicine for treating liver cancer and hepatic injury due to hepatitis B |
| CN105169274A (en) * | 2015-10-10 | 2015-12-23 | 崇州市地龙海龙生物制品开发研究所 | Preparation method of quick-acting liver pill |
| CN106620057A (en) * | 2016-12-12 | 2017-05-10 | 广西防城港常春生物技术开发有限公司 | Anti-hepatic fibrosis Zhuang medicine preparation and preparation method thereof |
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234381C (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100361689C (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN1193775C (en) | Rheumatoid disease treating capsule | |
| CN1234381C (en) | Medicine compositions for treating hepatitis, and its prepn. method | |
| CN1201782C (en) | Medicine composition for treating mammary gland proliferation, and its prepn. method | |
| CN1977852B (en) | Medicinal composition containing stilbene total glycoside and its use for pharmaceutical treating hepatitis B | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN1233388C (en) | Combination of medicine for treating hepatitis | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN1706453A (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN1895513A (en) | Medicine for treating oral lichen planus | |
| CN103301380B (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN1087617C (en) | Hepatitis curing capsule | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1435249A (en) | Chinese patent medicine for treating hyperlipidemia and fatty liver and preparing process thereof | |
| CN1903276A (en) | Medicinal composition for treating hepatitis B | |
| CN1086129C (en) | Hepatitis restoration pill | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN1253017A (en) | Medicine for treating appendicitis | |
| CN100337671C (en) | Chinese traditional medicine for treating thrombocytopenia | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN1814250A (en) | Chinese medicine composition for treating liver cirrhosis ascites and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: QIYUANYIDE MEDICINES INST., BEIJING Free format text: FORMER OWNER: ZHANG HUIFANG Effective date: 20030812 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030812 Applicant after: Beijing Qi Yuan Yi De Pharmaceuticals Research Center Applicant before: Zhang Huifang |
|
| ASS | Succession or assignment of patent right |
Owner name: XIANYANG BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: QIYUANYIDE MEDICINES INST., BEIJING Effective date: 20040303 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20040303 Applicant after: BUCHANG Group Applicant before: Beijing Qi Yuan Yi De Pharmaceuticals Research Center |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIANYANG BUCHANG PHARMACEUTICAL CO., LTD. Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: Hebei Dingxing 86188 army hospital Patentee after: BAODING BUCHANG TIANHAO PHARMACEUTICAL Co.,Ltd. Address before: The west section of Xianyang City Weiyang Road No. 123 Patentee before: BUCHANG Group |
|
| C56 | Change in the name or address of the patentee |
Owner name: BAODING TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Xinghua 072650 Hebei province Dingxing County Road No. 128 Patentee after: BAODING TIANHAO PHARMACEUTICAL Co.,Ltd. Address before: 072650 Hebei province Dingxing County 86188 army hospital Patentee before: BAODING BUCHANG TIANHAO PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060104 |
|
| CX01 | Expiry of patent term |